Imaging agent linked to false positives in Crohn's disease diagnosis

09/30/2008 | HealthImaging.com

The OctreoScan imaging agent, when used in neuroendocrine tumor detection, may cause false positive results in diagnosing Crohn's disease, Spanish researchers said. In a study of a patient suspected to have an ileal carcinoid tumor, the researchers obtained a positive OctreoScan and reported Crohn's disease after performing surgery and histological analysis. Immunohistochemical studies, however, did not reveal any somatostatin receptors, the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL